【Information】The innovative drug bebosa for acute leukemia was approved in China

Text/Yangcheng Evening News all-media reporter Yu Yanhong

On December 22, Pfizer announced on its official website that the State Drug Administration of China has approved Bebossa (oghaitulizumab for injection) for adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R B-ALL), which is also the world's first antibody-coupled drug (ADC) approved for the treatment of R/R B-ALL.

Photo/Visual China Infographic

Leukemia is a common tumor of the hematolymphatic system, and more than 80,000 new leukemia patients will be added to China in 2020. Acute lymphoblastic leukemia is one of the four main types of leukemia and is a malignant neoplastic disease in which B or T line cells originate in lymphocytes grow abnormally in the bone marrow. Abnormally proliferative blast cells can aggregate in the bone marrow and inhibit normal hematopoietic function, and can also invade tissues outside the bone marrow.

At present, the treatment of patients with acute leukemia in China is mainly chemotherapy, of which 40%-50% of adult patients will eventually experience recurrence, and the total survival rate of patients in five years is less than 10%. Under traditional standard chemotherapy regimens, treatment of patients with R/R ALL is difficult to achieve complete remission and long-term survival.

ADC drugs change the status quo of treatment in adult patients with R/R ALL. As one of the hot drugs in the current tumor immunotherapy, with its unique tumor specificity and efficacy, ADC drugs can not only expand the tumor treatment time window, but also minimize chemotherapy-related adverse reactions.

As one of the representative drugs of ADC, Bebosa (oga igalizumab for injection) can improve the complete response rate of acute leukemia treatment, so that more patients have the opportunity to undergo hematopoietic stem cell transplantation in the future, thereby achieving the purpose of long-term survival, which is expected to help the establishment of new treatment standards. (For more news, please pay attention to Yangcheng Pie pai.ycwb.com)

Source | Yangcheng Evening News Yangcheng Pie

Editor-in-charge | Cui Wencan